<DOC>
	<DOCNO>NCT00234520</DOCNO>
	<brief_summary>The aim study compare risk acromegaly patient develop valvular regurgitation receive lanreotide octreotide</brief_summary>
	<brief_title>A Study Evaluate Risk Developing Heart Condition Called Valvular Regurgitation Patients With Acromegaly Treated With Either Lanreotide Octreotide</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patient diagnosis Acromegaly Patient treat lanreotide octreotide dose form selection visit de novo patient due commence treatment within 2 week baseline Patient start treatment either lanreotide octreotide product available market country Patient must change treatment form lanreotide octreotide vice versa duration study Patients know significant valve abnormality prior treatment either lanreotide octreotide Patients receive treatment somatostatin analogue lanreotide octreotide 3 month Patients receive treatment GH antagonist 3 month Patients heart valve replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>